Payer / HTA meeting · Dr. Chloé Kimura

• Comparator checkpoint monotherapy
• Chemotherapy-free first line

• irAE management guide
• PD-L1 testing pathway infographic

1. What is the evidence for re-challenge with checkpoint inhibitors after progression on vantrelimab?
2. What was the median PD-L1 testing turnaround in the pivotal trial sites?

Payer / HTA meeting with thoracic medical oncologist at Hôpital Pitié-Salpêtrière. Discussed comparator checkpoint monotherapy, chemotherapy-free first line.